Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. - Wikidata - awgldk - TriplyDB

Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.

Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.

http://www.wikidata.org/entity/Q34332284

about

Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1 Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials.A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1 A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41.Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region Increased functional stability and homogeneity of viral envelope spikes through directed evolution.A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.Analysis of the disulfide bond arrangement of the HIV-1 envelope protein CON-S gp140 ΔCFI shows variability in the V1 and V2 regions.Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion.Human immunodeficiency virus: scientific challenges impeding candidate vaccines.A cationic nanoemulsion for the delivery of next-generation RNA vaccines.Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein.Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs Stability of a receptor-binding active human immunodeficiency virus type 1 recombinant gp140 trimer conferred by intermonomer disulfide bonding of the V3 loop: differential effects of protein disulfide isomerase on CD4 and coreceptor binding Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization Purification of recombinant vaccinia virus-expressed monomeric HIV-1 gp120 to apparent homogeneity.Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide.A functional interaction between gp41 and gp120 is observed for monomeric but not oligomeric, uncleaved HIV-1 Env gp140.Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.

P2860

Q27304735-3DCDCB1C-96EB-4A01-B177-4F97BE0BAC8D Q28476839-8B219F3C-C629-4BD6-807C-36C0797F5475 Q28534454-7712D2A9-FAED-49E2-BEB7-E18334B5AC4B Q28552786-328C3DB7-BE03-451C-8B3D-1C6DB1295D9E Q28730561-4ED66585-6494-49D4-B761-E183C97713B5 Q28732438-21D72518-FFBB-422E-BE39-D9593E3A3568 Q29307502-587C6DD4-226C-42AF-9F4F-57124BA0BED9 Q30332833-B31A4B20-231C-44CD-97F1-2D9AF5AFBB5F Q33648910-9B8247DE-2ACA-47A3-AB25-922216952BBC Q33877513-3FED4994-1231-482F-ABEE-8ED3117B8922 Q33883887-2777D551-AFD0-49DB-8EC3-9083D234CD52 Q34361680-B5D564F8-5FDB-4685-8C4D-3B62A030F937 Q34396095-2A898E79-9D6A-4EBD-902F-7F491212D341 Q34396912-69339451-B2AF-4FAD-975C-57C2FA4B04A5 Q34434813-25B39039-9F57-47D2-B4CD-2223B8FDD244 Q34466693-64A8CCA0-454C-423D-B5A8-D21ABAF4D1B3 Q34471760-BCC2C74B-BB65-4EF2-990A-5DDD2D5928D5 Q34611144-E9927210-607F-4DAC-A00D-6E1015E200C8 Q34743297-AC434E49-C36E-4E86-9A8C-215BE73E2C04 Q34784833-85016AD0-60CA-4A05-B240-8B55C886A0B7 Q35065249-F1E4DA7D-C824-412A-9CEC-473024CFEB69 Q35077716-7BA13C08-EF2F-4AEF-B901-D96639779DCB Q35110976-1FB98067-D71C-4E9B-94B0-AA9E46BF443D Q35173635-D55A57B2-8AEC-4E04-99B1-D5A58459B512 Q35558828-C25077F5-64FB-4BE9-98A3-8F7C1F1C1599 Q35589136-8C50F838-983E-429F-B847-25E5979333C2 Q35600305-32E6F720-271C-462A-93D1-66E4F28E31BD Q35666057-2FD13023-1BE0-4F60-A1BB-311C0C09CEDC Q35667479-EA134002-B45B-4652-81B2-AAB4596631D2 Q35677724-F3AF0FE6-D41E-4C0D-9A40-2AD52C624D84 Q35857416-86EECE3B-1475-471B-B1F9-ECC3D8085898 Q35861256-DF3F54D1-A010-4097-8E30-5648B665B667 Q36149102-77296BED-5C11-418C-991B-BDCC36CF6B21 Q36673173-0FF054E2-494F-43FD-9F3E-798BB4FDA2C5 Q36837815-CF847DC3-90D8-4EE0-BA30-AEBA6F60FAD2 Q37032195-C2B328C3-0890-4135-9E32-D544136C6C7F Q37033269-605EDA32-8836-480F-9E35-588FA9B2CDF8 Q37102810-016421BF-7792-4241-A1AE-FA36B595CAA8 Q37252789-FDA78293-D152-4D8C-AEB5-2CBDB6F3B830 Q37297052-FD4F81A7-1E23-456F-9A7C-3DD57043B5FB

P2860

Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.

http://www.wikidata.org/entity/Q34332284

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Purification and characterizat ...... human immunodeficiency virus.

@ast

Purification and characterizat ...... human immunodeficiency virus.

@en

Purification and characterizat ...... human immunodeficiency virus.

@nl

type

label

Purification and characterizat ...... human immunodeficiency virus.

@ast

Purification and characterizat ...... human immunodeficiency virus.

@en

Purification and characterizat ...... human immunodeficiency virus.

@nl

prefLabel

Purification and characterizat ...... human immunodeficiency virus.

@ast

Purification and characterizat ...... human immunodeficiency virus.

@en

Purification and characterizat ...... human immunodeficiency virus.

@nl

P1433

Q34332284-9090FF8C-579B-45B0-B5D0-A85689195F92

P1476

Q34332284-49C2FE73-68FE-4725-A4B6-BAD98E234872

P2093

Q34332284-1D41B4AC-BD26-4639-9BDD-6BEBBB4E766E

Q34332284-28475853-2B4D-4BE5-BD54-768D1AD4536B

Q34332284-42AF07FE-B64D-4905-A58D-7BAFD3B3B679

Q34332284-44768799-C032-434A-B1BE-8AC9A0A8C899

Q34332284-57921D61-9C05-4D44-B0C3-ADB73AA09F1F

Q34332284-60D15CDA-8E01-4650-A20B-6100E1548B40

Q34332284-636337FB-C3DA-4050-9312-70A460ECA894

Q34332284-B0399E96-77DB-4856-A68F-48FC12D87CCA

Q34332284-D64C622C-D12C-4E07-886B-710E39D21A2F

Q34332284-D958CD18-6D3D-46F0-AEFE-B127E107BE6A

P2860

Q34332284-03EE8C58-4C65-4F31-B947-A91E7B2B51A3

Q34332284-04B8D282-E8A2-4D7B-9B6E-5049C0F719AD

Q34332284-054EFC5C-2935-45F1-A772-3AA15D884616

Q34332284-0C425DE3-3FD9-4193-857E-7D066276BDCA

Q34332284-103DEEE1-0E51-48F3-8DDA-C9285072C2CA

Q34332284-1100C63D-A7D5-4119-B873-FCA77E40D8E3

Q34332284-14782978-7726-4623-A23B-732E43E191E5

Q34332284-15F4951D-5E0C-4F3B-B9C3-8A911E1AFCF2

Q34332284-16815D63-3F37-42D0-ACF5-0A290826AB04

Q34332284-18DE8513-4219-43C8-9591-8D9D4139593D

P304

Q34332284-8AF481D4-17FA-426E-9FB2-1AABAAF710DC

P31

Q34332284-443B7D96-CB86-41E9-9E6A-6FE0F8FD2773

P356

Q34332284-A4D03842-CE40-47A9-86CA-D1857596227B

P407

Q34332284-F9276C94-E235-412C-81AC-A6D0262D6A57

P433

Q34332284-55154EC3-A896-45C2-AE1F-BB0B7C92480F

P478

Q34332284-55640AF9-0CE7-4CAA-8103-18E431421585

P577

Q34332284-AD0057D5-BA75-484D-ADEF-E8DF7D224C21

P5875

Q34332284-BF17635E-0967-4192-B4F0-4559C4F49B26

P698

Q34332284-79D8F801-B2EF-4A2E-B537-9CF85B7FDB27

P932

Q34332284-502F5CAA-B479-4780-8E01-A01F71320149

P356

JVI.76.6.2835-2847.2002

P1433

Journal of Virology

P1476

Purification and characterizat ...... human immunodeficiency virus.

@en

P2093

Anne Fong

http://www.w3.org/2001/XMLSchema#string

Elaine Kan

http://www.w3.org/2001/XMLSchema#string

Harold Legg

http://www.w3.org/2001/XMLSchema#string

Indresh K Srivastava

http://www.w3.org/2001/XMLSchema#string

Jeffrey B Ulmer

http://www.w3.org/2001/XMLSchema#string

John J Donnelly

http://www.w3.org/2001/XMLSchema#string

Leonidas Stamatatos

http://www.w3.org/2001/XMLSchema#string

Louisa Leung

http://www.w3.org/2001/XMLSchema#string

Mark Wininger

http://www.w3.org/2001/XMLSchema#string

Stephen R Coates

http://www.w3.org/2001/XMLSchema#string

P2860

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

Codon usage limitation in the expression of HIV-1 envelope glycoprotein

Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly

Core structure of gp41 from the HIV envelope glycoprotein

Atomic structure of the ectodomain from HIV-1 gp41

Atomic structure of a thermostable subdomain of HIV-1 gp41

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

P304

2835-2847

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.76.6.2835-2847.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11499899

http://www.w3.org/2001/XMLSchema#string

P698

11861851

http://www.w3.org/2001/XMLSchema#string

P932

135955

http://www.w3.org/2001/XMLSchema#string